Core Insights - Verona Pharma plc is presenting two posters on additional analyses from its Phase 3 ENHANCE studies of Ohtuvayre (ensifentrine) for COPD treatment at the European Respiratory Society International Congress 2025 [1][3] - Ohtuvayre is a first-in-class selective dual inhibitor of PDE3 and PDE4, combining bronchodilator and non-steroidal anti-inflammatory effects, marking the first novel inhaled mechanism for COPD maintenance treatment in over 20 years [2][4] Group 1: Ohtuvayre's Clinical Data - The posters focus on subgroup analyses demonstrating the benefits of ensifentrine on lung function, exacerbation rates, and COPD symptoms, including dyspnea and quality of life based on baseline dyspnea levels [3] - Poster 3613 presents the effect of ensifentrine on COPD symptoms and quality of life, while Poster 3614 discusses its impact on lung function and exacerbations [3] Group 2: Company Overview - Verona Pharma is dedicated to developing innovative therapies for chronic respiratory diseases with significant unmet medical needs, with Ohtuvayre being its first commercial product [6] - The company is also developing a fixed-dose combination of ensifentrine and glycopyrrolate for COPD maintenance treatment [4]

The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeksThe phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeksThe safety profile of astegolimab was consistent with previously reported data, with no new safety signals identifiedAnalysis of the ALIENTO and ARNASA data will be discussed with regulatory ...

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease ("COPD"), two fro ...